The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

During the first meeting of the Global Think-tank on Steatotic Liver Disease, supported by the Barcelona Institute for Global ...

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

Take a fascinating look back at the science and technology advances that shaped medicine’s past and will define its future.

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.